NO167758C - Fremgangsmaate ved fremstilling av humane monoklonale antistoffer mot serotypiske lipopolysakkarid-determinanter. - Google Patents

Fremgangsmaate ved fremstilling av humane monoklonale antistoffer mot serotypiske lipopolysakkarid-determinanter.

Info

Publication number
NO167758C
NO167758C NO85852093A NO852093A NO167758C NO 167758 C NO167758 C NO 167758C NO 85852093 A NO85852093 A NO 85852093A NO 852093 A NO852093 A NO 852093A NO 167758 C NO167758 C NO 167758C
Authority
NO
Norway
Prior art keywords
crl
monoclonal antibodies
human monoclonal
serotypic
procedure
Prior art date
Application number
NO85852093A
Other languages
English (en)
Norwegian (no)
Other versions
NO167758B (no
NO852093L (no
Inventor
Anthony A Siadak
Mark E Lostrom
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24460190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO167758(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Publication of NO852093L publication Critical patent/NO852093L/no
Publication of NO167758B publication Critical patent/NO167758B/no
Publication of NO167758C publication Critical patent/NO167758C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/803—Antibody or antigen-binding fragment thereof that binds gram-negative bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y10S424/808—Human
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y10S530/865—Human

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO85852093A 1984-05-25 1985-05-24 Fremgangsmaate ved fremstilling av humane monoklonale antistoffer mot serotypiske lipopolysakkarid-determinanter. NO167758C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61418484A 1984-05-25 1984-05-25

Publications (3)

Publication Number Publication Date
NO852093L NO852093L (no) 1985-11-26
NO167758B NO167758B (no) 1991-08-26
NO167758C true NO167758C (no) 1991-12-04

Family

ID=24460190

Family Applications (1)

Application Number Title Priority Date Filing Date
NO85852093A NO167758C (no) 1984-05-25 1985-05-24 Fremgangsmaate ved fremstilling av humane monoklonale antistoffer mot serotypiske lipopolysakkarid-determinanter.

Country Status (16)

Country Link
US (1) US4834975A (da)
EP (1) EP0163493B1 (da)
JP (1) JPS6169796A (da)
KR (1) KR850008282A (da)
AT (1) ATE62021T1 (da)
AU (1) AU600222B2 (da)
DE (1) DE3582274D1 (da)
DK (1) DK233385A (da)
ES (1) ES8702792A1 (da)
FI (1) FI89278C (da)
GR (1) GR851234B (da)
HU (1) HU202927B (da)
IE (1) IE58411B1 (da)
IL (1) IL75277A (da)
NO (1) NO167758C (da)
ZA (1) ZA853888B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
JPS61155398A (ja) * 1984-12-28 1986-07-15 Teijin Ltd 抗緑膿菌ヒトモノクロ−ナル抗体及びその製造法並びにそれを有効成分とする治療剤
EP0233289B1 (en) * 1984-12-26 1993-03-10 Teijin Limited Hybridomas producing anti-pseudomonas aeruginosa human monoclonal antibody
JPS61152280A (ja) * 1984-12-26 1986-07-10 Teijin Ltd 抗緑膿菌ヒト抗体を産生する形質転換細胞及びその製造法並びにその使用方法
EP0215131B1 (en) * 1985-03-11 1992-06-17 Teijin Limited E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
US5179001A (en) * 1985-09-27 1993-01-12 The Regents Of The University Of California Detection and monitoring of chronic and gram-negative infection
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
EP0494085A1 (en) 1985-09-27 1992-07-08 The Regents Of The University Of California Monoclonal antibodies binding determinants of gram negative bacteria
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
IL81370A (en) * 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
ZA87863B (en) * 1986-02-07 1987-09-30 Genetic Systems Corp Cross-protective human monoclonal antibody compositions
ES2009365A6 (es) * 1986-04-24 1989-09-16 Univ California Procedimiento de otencion de anticuerpos monoclonales para bacterias gram-negativas.
GB8610202D0 (en) * 1986-04-25 1986-05-29 Technology Licence Co Ltd Monoclonal antibodies
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
ZA878610B (en) * 1986-11-20 1989-06-28 Minnesota Mining & Mfg Method for the evaluation of oral microbes
US5521085A (en) * 1986-12-15 1996-05-28 Mitsui Toatsu Chemicals, Inc. Transformed cell lines producing human monoclonal antibodies specific for Pseudomonas aeruginosa serotypes
AU1807188A (en) * 1987-04-10 1988-11-04 Xoma Corporation Human monoclonal antibodies binding determinants of gram negative bacteria
ES2045027T3 (es) * 1987-08-10 1994-01-16 Miles Inc Igm purificadas.
JPH01197500A (ja) * 1988-01-29 1989-08-09 Sumitomo Chem Co Ltd ヒトモノクローナル抗体
GB2218703B (en) * 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US5439665A (en) * 1988-07-29 1995-08-08 Immunomedics Detection and treatment of infectious and inflammatory lesions
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
JPH02283294A (ja) * 1989-04-24 1990-11-20 Sumitomo Chem Co Ltd ヒトモノクローナル抗体
US5233024A (en) * 1991-04-09 1993-08-03 The Brigham & Women's Hospital Anti-idiotypic monoclonal antibodies for mucoid pseudomonas aeruginosa, their preparation and use
US5824310A (en) * 1991-10-22 1998-10-20 The United States Of America As Represented By The Department Of Health And Human Services Lipopplysaccharide conjugate vaccines
CA2085448C (en) * 1991-12-24 2003-11-18 Masakazu Tsuchiya Process for extracting endotoxin
US5610031A (en) * 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US5562902A (en) * 1994-03-14 1996-10-08 Arp Biomed, Inc. Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin
US5807694A (en) * 1995-09-07 1998-09-15 Economic Innovation And Technology Council, University Of Manitoba Detection of salmonella enteritidis and other pathogenic microorganisms and monoclonal antibody useful therefor
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
ATE339964T1 (de) * 1997-05-15 2006-10-15 Trillium Therapeutics Inc Verfahren um immunkoagulation zu modulieren
US6790661B1 (en) 1999-07-16 2004-09-14 Verax Biomedical, Inc. System for detecting bacteria in blood, blood products, and fluids of tissues
WO2001061305A2 (en) * 2000-02-15 2001-08-23 Fit Biotech Oyj Plc Immunoassays detecting or making use of at least two rubber latexallergens
ATE458006T1 (de) * 2003-05-14 2010-03-15 Kenta Biotech Ag Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa
US20120114657A1 (en) 2009-04-09 2012-05-10 Kenta Biotech Ag Human Monoclonal Antibody Specific for Lipopolysaccharides (LPS) of Serotype IATS 01 of Pseudomonas Aeruginosa
KR20130048199A (ko) * 2010-02-18 2013-05-09 심포젠 에이/에스 녹농균의 혈청형 ｅ 지질다당류에 대한 항체
EP2361989A1 (en) * 2010-02-26 2011-08-31 Kenta Biotech AG Assays and kits for serotyping Pseudomonas aeruginosa and oligonucleotide sequences useful in such methods and kits

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU530649B2 (en) * 1981-01-28 1983-07-21 Coats Patons Plc Method of manufacturing monoclonal antibodies and capable of manufacturing such antibodies
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
JPS5929622A (ja) * 1982-08-10 1984-02-16 Meiji Seika Kaisha Ltd モノクロ−ナル抗体、その製造法およびその用途
CA1262238C (en) * 1982-09-30 1989-10-10 HUMAN MONOCLONAL ANTIBODIES AGAINST BACTERIAL TOXINS
JPH0776240B2 (ja) * 1983-05-06 1995-08-16 ベロス グル−プ エンドトキシンコア−と反応性のモノクロ−ナル抗体
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria

Also Published As

Publication number Publication date
JPS6169796A (ja) 1986-04-10
EP0163493B1 (en) 1991-03-27
EP0163493A3 (en) 1986-07-02
FI89278C (fi) 1993-09-10
ES543474A0 (es) 1987-01-16
NO167758B (no) 1991-08-26
IE851302L (en) 1985-11-25
ES8702792A1 (es) 1987-01-16
ZA853888B (en) 1986-01-29
FI852029A0 (fi) 1985-05-21
KR850008282A (ko) 1985-12-16
IL75277A (en) 1990-02-09
HU202927B (en) 1991-04-29
ATE62021T1 (de) 1991-04-15
AU4285885A (en) 1985-11-28
AU600222B2 (en) 1990-08-09
GR851234B (da) 1985-07-01
FI89278B (fi) 1993-05-31
US4834975A (en) 1989-05-30
DK233385A (da) 1985-11-26
DK233385D0 (da) 1985-05-24
DE3582274D1 (de) 1991-05-02
FI852029L (fi) 1985-11-26
IE58411B1 (en) 1993-09-22
NO852093L (no) 1985-11-26
HUT38123A (en) 1986-04-28
IL75277A0 (en) 1985-09-29
EP0163493A2 (en) 1985-12-04

Similar Documents

Publication Publication Date Title
NO167758C (no) Fremgangsmaate ved fremstilling av humane monoklonale antistoffer mot serotypiske lipopolysakkarid-determinanter.
SE8605295L (sv) Monoklonala antikroppar som er korsreaktiva och korsprotektiva mot p. aeruginosa-sero-typer
AU545225B2 (en) Hybrid cell line
IL59919A (en) Monoclonal antibody of class igg to human helper t cells,its preparation and pharmaceutical and diagnostic compositions containing it
NO162613C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive diarylacetylener.
NO159888C (no) Monoklonalt antistoff.
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
IT1210589B (it) Procedimento per la preparazione dicomposti pirimidinici dotati di attivita' farmacologica particolarmente per il trattamento di infezioni batteriche loro intermedi prodotto ottenuto e composizioni farmaceutiche che li contengono
DE3377063D1 (en) Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
NO159887C (no) Monoklonalt antistoff.
ES2009140A6 (es) Un metodo de produccion de anticuerpos monoclonales humanos de proteccion cruzada y de composiciones que los contienen.
GR71724B (da)
IT8009551A0 (it) E-5-(2-alogenovinil-)-2'deossicitidine, loro metodo di preparazione e loro impiego per il trattamentodi malattie da virus
IT8419950A0 (it) Contengono i prodotti emichetali di (8s)-8-fluoroeritromi cine, il procedimento per la loro preparazione e le formulazioni adatte alla somministrazione orale che
Gregory et al. IgA antibodies to oral and ocular bacteria in human external secretions
Henney et al. Natural killer cells. In vitro and in vivo.
FR2568585B1 (fr) Nouvelles cellules hybrides secretant des anticorps anti-idiotypiques, nouveaux anticorps monoclonaux secretes par lesdites cellules hybrides, leur preparation et leur application
Lissandrello-Steubing Immunoglobulins in periodontal disease
EP0243174A3 (en) Monoclonal antibodies to pseudomonas aeruginosa exoenzyme s, their preparation and use
IL80918A (en) Monoclonal antibodies cross-reactive and cross-protective against p.aeruginosa serotypes and pharmaceutical compositions and kits containing said antibodies
IT7927837A0 (it) Procedimento migliorato per la fermentazione dell'etanolo.
IT8323603A0 (it) Esteri dell'o-metossifenolo ad azione anti-infiammatoria e espettorante, procedimento per laloro preparazione e composizione farmaceutiche che li contengono.